Claims for Patent: 10,953,000

Summary for Patent: 10,953,000

Title:	Combination of pimavanserin and cytochrome P450 modulators
Abstract:	A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
Inventor(s):	Parkinson; Andrew (Shawnee, KS)
Assignee:	ACADIA Pharmaceuticals Inc. (San Diego, CA)
Application Number:	16/087,604
Patent Claims:	1. A method of treating psychosis in a patient being administered 34 mg of pimavanserin once daily and in need thereof, wherein said patient is then in need of being treated concurrently with a strong CYP3A4 inhibitor in addition to the pimavanserin, comprising: orally administering to the patient a reduced dose of 10 mg of pimavanserin or a pharmaceutically acceptable salt thereof once daily in addition to administration of the strong CYP3A4 inhibitor to said patient, wherein the strong CYP3A4 inhibitor is selected from the group consisting of: ketoconazole, clarithromycin, indinavir, and itraconazole. 2. The method of claim 1, wherein the 10 mg of pimavanserin is a unit dose comprising pimavanserin tartrate. 3. The method of claim 1, wherein the strong CYP3A4 inhibitor is ketoconazole. 4. The method of claim 1, wherein the psychosis is Parkinson's disease psychosis or Alzheimer's disease psychosis. 5. The method of claim 1, wherein the psychosis is secondary to a neurodegenerative disorder. 6. A method of treating hallucinations or delusions associated with Parkinson's disease psychosis in a patient being administer being administered 34 mg of pimavanserin once daily and in need thereof, wherein said patient is then in need of being treated concurrently with a strong CYP3A4 inhibitor in addition to the pimavanserin, comprising: orally administering to said patient a reduced dose of 10 mg of pimavanserin or a pharmaceutically acceptable salt thereof once daily in addition to administration of the strong CYP3A4 inhibitor to said patient, wherein the strong CYP3A4 inhibitor is selected from the group consisting of ketoconazole, clarithromycin, indinavir, and itraconazole.